Skip to main content

Table 3 Summary of therapy to NC cases

From: Incidence of NUT carcinoma in Western Australia from 1989 to 2014: a review of pediatric and adolescent cases from Perth Children’s Hospital

Patient

Tumor site

Year of diagnosis

Chemotherapy

Radiotherapy

2

Lung

1989

Ifosfamide (1800 mg /m2/day) and VP16 (100 mg/m2/day)

60.4 Gy

3

Sternal mass

1996

aCCG 0894: carboplatinum (400 mg/m2/day), VP16 (100 mg/m2/day) and ifosfamide (1800 mg /m2/day)

Autologous peripheral hematopoietic stem cell rescue with melphalan (200 mg/m2).

60.4 Gy

4

Nasopharynx

1996

aCCG 0894: carboplatinum (400 mg/m2/day), VP16 (100 mg/m2/day) and ifosfamide (1800 mg /m2/day)

bIFRT 75 Gy (supraclavicular fossa) and 52.5 Gy (posterior region of the neck)

6

Bronchus

2007

Five cycles of ifosfamide (1200 mg/m2/day) and doxorubicin (37.5 mg/m2/day) given with dexrazoxane as cardioprotectant

45 Gy

11

Paraspinal L4

1994

aCCG 6902, vincristine (1.5 mg/m2), actinomycin (0.15 mg/kg/day) and ifosfamide (1800 mg/m2/day)

Subsequent to second debulking, cyclophosphamide (2.2 g/m2), VP16 (100 mg/m2/day). Peripheral hematopoietic stem cell rescue with melphalan (200 mg/m2).

63.8 Gy

  1. aCCG Children’s Cancer Group
  2. bIFRT involved field radiation therapy